Producer
Fresenius Kabi (injectable opioids)
5
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
5 inputs Fresenius Kabi (injectable opioids) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
pharmaceutical
Propofol Injectable Anesthetic (Diprivan generic) →
pharmaceutical
IV Parenteral Nutrition Solutions (TPN Bags) →
pharmaceutical
Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel) →
pharmaceutical
Injectable Hospital Antibiotics (Vancomycin, Pip-Tazo, Cefepime) →
pharmaceutical
Injectable opioid vials (morphine, hydromorphone, fentanyl IV) →
Where it shows up
Goods downstream
Essential goods that depend on something Fresenius Kabi (injectable opioids) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Pharmaceuticals (IV Drugs)
42%Clinical Nutrition
28%Medical Devices (Infusion / Transfusion / Cell Therapy)
20%Biosimilars
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Fresenius Kabi — known in supply chain shortages as a hospital injectable opioid manufacturer — is simultaneously the #2 global supplier of IV parenteral nutrition (PN) solutions: the sterile multi-chamber bags of amino acids, lipids, glucose, and electrolytes that keep premature neonates, ICU patients, and oncology patients alive when they cannot absorb food through the gut. Every NICU, every ICU, and every oncology ward in the developed world depends on Kabiven and Smofkabiven bags from Fresenius Kabi. The same German company supplying morphine drips to pain management is supplying the intravenous 'food' that keeps a 24-week premature infant alive in the neonatal ICU.
Fresenius Kabi ↗Capacity2023
Fresenius Kabi's Smofkabiven parenteral nutrition formulation uses a proprietary mixed lipid emulsion (SMOF: Soybean/MCT/Olive/Fish oil) designed to reduce the pro-inflammatory effects of pure soybean-oil PN in ICU patients. The fish oil component (EPA and DHA omega-3 fatty acids) requires pharmaceutical-grade fish oil from certified sources. Fresenius Kabi sources pharmaceutical-grade fish oil from Norwegian and Icelandic suppliers — creating an agricultural/marine supply chain dependency (North Sea fish stocks) embedded within a hospital critical care drug. A collapse in certified pharmaceutical-grade fish oil supply would force substitution to standard soybean-oil-only PN formulations, potentially worsening outcomes in critically ill patients with inflammatory conditions.
Fresenius Kabi ↗Origin2024
Fresenius Kabi is a subsidiary of Fresenius SE & Co. KGaA, a German diversified healthcare conglomerate that also owns Fresenius Medical Care (the world's largest dialysis company), Helios (the largest private hospital operator in Europe and Spain), and Fresenius Vamed (hospital services). Total Fresenius SE revenue in 2023 was approximately €22B — making it one of the largest healthcare companies in the world by revenue. Fresenius Kabi alone (€7.8B) is larger than most standalone pharmaceutical companies. Its scope — from IV nutrition bags and injectable anesthetics to CAR-T equipment and hospital dialysis — makes the Fresenius group a systemic counterparty to virtually every healthcare institution in the developed world.
Fresenius SE & Co. KGaA ↗